Next Article in Journal
The Impact of a Structured Outpatient Parenteral Antimicrobial Therapy (OPAT) Programme on Quality of Care, Optimisation of Antimicrobial Use, and Healthcare Costs: A Retrospective Cohort Study
Previous Article in Journal
Antimicrobial Resistance Phenotypes and Genotypes of Escherichia coli Isolates from Artisanal Minas Frescal Cheeses from the Federal District, Brazil
 
 
antibiotics-logo
Article Menu

Article Menu

Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antimicrobial Resistance Profiles of Bacteria Isolated from the Animal Health Sector in Zambia (2020–2024): Opportunities to Strengthen Antimicrobial Resistance Surveillance and Stewardship Programs

by
Taona Sinyawa
1,2,*,
Fusya Goma
3,
Chikwanda Chileshe
4,5,
Ntombi B. Mudenda
6,
Steward Mudenda
4,7,8,*,
Amon Siame
9,
Fred Mulako Simwinji
9,
Mwendalubi Albert Hadunka
9,
Bertha Chibwe
9,
Kaunda Kaunda
9,
Geoffrey Mainda
10,
Bruno S. J. Phiri
11,
Maisa Kasanga
4,12,
Webrod Mufwambi
7,
Samson Mukale
4,
Andrew Bambala
12,
Jimmy Hangoma
13,
Nawa Mabuku
14,
Benson Bowa
1,
Obrian Kabunda
1,
Mulumbi Nkamba
1,
Ricky Chazya
4,
Ruth Nakazwe
12,
Mutila Malambo
4,
Zoran Muhimba
4,12,
Steven Mubamba
4,
Morreah Champo
4,
Mercy Mukuma
15,
George Dautu
1,
Chileshe Lukwesa
4,
O-Tipo Shikanga
16,
Freddie Masaninga
16,
Mpela Chibi
16,
Sandra Diana Mwadetsa
16,
Theodora Savory
9,
Joseph Yamweka Chizimu
4,
John Bwalya Muma
2,
Charles Maseka
3 and
Roma Chilengi
4
add Show full author list remove Hide full author list
1
Central Veterinary Research Institute, Ministry of Fisheries and Livestock, Chilanga, Lusaka 10101, Zambia
2
Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
3
Department of Veterinary Services, Ministry of Fisheries and Livestock, Lusaka 15100, Zambia
4
Zambia National Public Health Institute, Stand 1186, Corner of Chaholi and Addis Ababa Roads, Rhodes Park, Lusaka 10101, Zambia
5
Department of Biomedical Sciences, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
6
Department of Clinical Studies, University of Zambia, Lusaka 10101, Zambia
7
Department of Pharmacy, University of Zambia, Lusaka 10101, Zambia
8
Education and Continuous Professional Development Committee, Pharmaceutical Society of Zambia, Lusaka 10101, Zambia
9
Centre for Research in Infectious Diseases, Lusaka 10101, Zambia
10
Food and Agriculture Organization of the United Nations (FAO), Chaholi Road, Rhodes Park, Lusaka 10101, Zambia
11
Department of Paraclinical Studies, School of Veterinary Medicine, University of Zambia, Lusaka 10101, Zambia
12
University Teaching Hospital, Ministry of Health, Lusaka 10101, Zambia
13
Department of Pharmacy, School of Health Sciences, Levy Mwanawasa Medical University, Lusaka 10101, Zambia
14
Enhanced Smallholder Livestock Investment Project, Plot No. 1, Gizenga Road, Woodlands, Lusaka 10101, Zambia
15
School of Agriculture, University of Zambia, Lusaka 10101, Zambia
16
Department of Health, World Health Organization, Lusaka 10101, Zambia
*
Authors to whom correspondence should be addressed.
Antibiotics 2025, 14(11), 1102; https://doi.org/10.3390/antibiotics14111102
Submission received: 19 August 2025 / Revised: 18 September 2025 / Accepted: 28 September 2025 / Published: 2 November 2025

Abstract

Background/Objectives: Antimicrobial resistance (AMR) is a major global health threat that undermines treatment in humans and animals. In Zambia, where livestock production underpins food security and livelihoods, AMR challenges are aggravated by limited surveillance, weak diagnostics, and poor regulatory enforcement, facilitating the spread of resistant pathogens across the human–animal–environment interface. This study aims to analyse AMR patterns of bacterial isolates collected from Zambia’s animal health sector between 2020 and 2024, to generate evidence that informs national AMR surveillance, supports antimicrobial stewardship (AMS) interventions, and strengthens One Health strategies to mitigate the spread of resistant pathogens. Methods: We conducted a retrospective descriptive analysis of previously collected routine laboratory data from five well-established animal health AMR surveillance sentinel sites between January 2020 and December 2024. Data were analysed by year, sample type, and antimicrobial susceptibility testing (AST) profiles using WHONET. Results: A total of 1688 samples were processed, with faecal samples accounting for 87.6%. Animal environmental samples (feed, manure, litter, abattoir/meat processing floor, wall, and equipment surface swabs) (collected from abattoirs, water, and farms) increased significantly over time (p = 0.027). Overall, Escherichia coli (E. coli) (50.4%) and Enterococcus spp. (30%) were the most frequently isolated bacteria. E. coli exhibited high resistance to tetracycline (74%) and ampicillin (72%) but remained susceptible to aztreonam (98%), nitrofurantoin (95%), and imipenem (93%). Enterococcus spp. were susceptible to penicillin (84%) and ampicillin (89%) but showed borderline resistance to vancomycin (53%) and linezolid (50%). Klebsiella spp. demonstrated resistance to ciprofloxacin (52%) and gentamicin (40%), whereas Salmonella spp. remained highly susceptible. Notably, resistance to amoxicillin/clavulanic acid rose sharply from 22.2% to 81.8% (p = 0.027). Across 1416 isolates, high levels of multidrug resistance (MDR) were observed, particularly in E. coli (48.4%) and K. pneumoniae (18.6%), with notable proportions progressing toward possible Extensively Drug-Resistant (XDR) and Pan-Drug-Resistant (PDR) states. Conclusions: The findings of this study reveal rising resistance to commonly used antibiotics in the animal health sector. Despite the lack of molecular analysis, our findings underscore the urgent need for AMS programs and integrated AMR surveillance under Zambia’s One Health strategy.

1. Introduction

Antimicrobial resistance (AMR), the failure of microorganisms to respond to antimicrobials to which they were once susceptible, is increasingly being recognised as a global public health and economic threat [1,2,3,4]. This phenomenon is currently referred to as the silent pandemic [3,5,6,7,8]. The overall health of humans, animals, and the environment is at dire risk, manifesting in compounded effects on food security and sustainable development [9,10]. Largely driven by the misuse and overuse of antimicrobials, livestock production systems are noted to be significant drivers of the rise and propagation of AMR [11]. The estimated global impact of AMR, if left unchecked, will lead to as high as 10 million deaths annually, with concomitant economic losses reaching USD 100 trillion by 2050 [12,13,14]. Evidence has shown an increase in antimicrobial use (AMU) in the animal sector, coupled with poor monitoring and surveillance, especially in most low- and middle-income countries (LMICs) [15,16,17,18,19,20]. This further results in the emergence and spread of AMR across the human–animal–environment continuum [21,22,23,24].
Drivers of AMR in the animal health sector have been reported in various studies [22,25,26,27]. The development of AMR in the animal health sector is largely due to the use of antimicrobials for therapy, metaphylaxis, prophylaxis, and growth promotion [28,29,30]. For example, evidence has indicated that the inappropriate use of antimicrobials in food-producing animals is a major driver of AMR [31,32]. This is coupled with using antimicrobials for growth promotion, increased production, and prophylaxis of diseases in the animal health sector [29,30,33,34]. Alongside this, access to antimicrobials without a valid prescription contributes to the development and spread of AMR [29,35,36,37,38]. Further, the lack of knowledge and awareness of AMU and AMR among farmers contributes to inappropriate use of antimicrobials and the emergence and spread of AMR [39,40,41]. Furthermore, veterinary antimicrobials contaminate the environment and expose microbes to these drugs, raising the potential for AMR emergence and spread [42]. Therefore, this calls for integrated AMR surveillance using a One Health approach because drug-resistant pathogens can cause infections in humans, animals, plants, and the environment [2,43,44,45].
Bacterial resistance to antibiotics is facilitated by a variety of mechanisms across bacterial genera [3,46,47,48]. The transfer of virulence and AMR genes across bacterial genera primarily occurs through horizontal gene transfer mechanisms such as conjugation, transformation, and transduction, often facilitated by mobile genetic elements like plasmids, transposons, and integrons [49]. These processes enable bacteria to rapidly acquire and disseminate resistance traits, even across unrelated species. Several factors accelerate this transmission, including excessive and inappropriate use of antimicrobials in livestock, intensive farming practices, inadequate biosecurity measures, and poor infection prevention and control [50,51,52]. Additionally, the close interaction between humans, animals, and the environment creates reservoirs that sustain resistant strains [53,54]. Together, these drivers intensify selective pressure, enhance bacterial adaptation, and promote the persistence and spread of AMR in animal health and beyond [22,55,56].
AMR surveillance reporting to global platforms like FAO InFARM has harmonised national AMR data with antimicrobial consumption (AMC) data via the ANImal antiMicrobial USE (ANIMUSE) WOAH global platform [57,58,59]. Effective surveillance, coupled with Antimicrobial Stewardship (AMS) programs, is an essential tool in mitigating the threat of AMR in the animal health sector [57,60,61]. As surveillance typically provides data on resistance patterns, it thus gives guidance on the formulation of treatment guidelines, policy development, and targeted interventions [45,62,63,64,65]. Stewardship programs promote rational AMU, as well as improved infection prevention practices, leading to enhanced overall quality of veterinary care [2,37,66,67,68,69,70,71].
Zambia, a country in the sub-Saharan African (SSA) region, developed a multisectoral National Action Plan (NAP) on AMR in 2017, having adapted it from the Global Action Plan on AMR [72]. This laid the foundation for an integrated AMR surveillance, key to which was the need for a well-coordinated, multi-pronged, One Health approach that integrated the human, animal, and environmental sectors as a result [73]. Arising from this, the animal health sector in Zambia selected Escherichia coli (E. coli), Enterococcus spp. and Salmonella spp. as priority microorganisms, aligning with global target bacteria for AMR monitoring and surveillance in food-producing animals, in light of their relevance to public health [60].
There is evidence of AMR in the animal health sector in Zambia based on previous studies [25,71,74,75,76,77,78,79,80,81,82,83]. The burden of AMR in the Zambian animal health sector has been reported to be due to inadequate knowledge and awareness of AMR among farmers, lack of diagnostic capacity, access to antibiotics without prescriptions, and inadequate enforcement of laws that restrict the use of antimicrobials in animals [25,41,84,85]. However, there is a paucity of information regarding the AMR profiles of bacteria isolated from the animal health sentinel sites in Zambia. It is against this background that this study investigated the AMR profiles of bacteria isolated from the animal health sector in Zambia between 2020 and 2024.
By analysing trends in resistance, distribution of key pathogens, and patterns of antimicrobial susceptibility (AST), this study identifies key opportunities to strengthen AMR surveillance and AMS programs. The findings aim to support evidence-based decision-making and contribute to the ongoing implementation of the One Health approach to AMR containment in Zambia. Furthermore, the findings from this study are expected to guide the development of context-specific strategies, ensuring that policies and interventions are both effective and efficiently tailored to local conditions.

2. Results

2.1. Sample Distribution and Trends over the Five Years (2020–2024)

In Zambia, AMR surveillance data collection follows the integrated AMR surveillance framework [73]. Samples were processed in established AMR surveillance laboratories, including public laboratories (Central Veterinary Research Institute, and the Choma, Chipata, and Mongu Provincial Veterinary Diagnostic Laboratories), as well as academia (the University of Zambia Public Health Laboratory), before being tested for resistance and analysed using WHONET. The results showed that the majority of the samples processed between 2020 and 2024 were faecal at (n = 1478, 87.6%), indicating a strong focus on gastrointestinal zoonotic pathogen surveillance, as shown in Table 1. In the initial three years of animal health AMR surveillance, the focus was primarily on poultry cloacal swab/faecal samples, from which E. coli and Salmonella spp. were commonly isolated [86]. Faecal sample throughput declined marginally (p = 0.086), hinting at logistical delays or reduced sampling in animal health surveillance. Over the five years, the sample throughput did not increase significantly overall, except for animal environmental samples (feed, manure, litter, abattoir/meat processing floor, wall, and equipment surface swabs) (n = 169, 10%) that showed a significant increase, possibly reflecting heightened focus on biosecurity monitoring or environmental contamination surveillance. Meat samples (n = 26, 1.5%) and food samples (n = 15, 0.9%) were minimal, suggesting a limited emphasis on food safety or post-mortem diagnostics in this period.

2.2. Microbial Isolates Profile over Time (2020 to 2024)

Figure 1 shows the frequency and percentage of the common isolates over the five years. E. coli (n = 850, 56.5%) and Enterococcus spp. (n = 507, 33.7%) were the most prevalent isolates, likely due to their ubiquity in zoonotic gut microbiota and role in AMR spread. Other pathogens included Klebsiella spp., (n = 59, 3.9%), Salmonella spp., (n = 27, 1.8%), and other Gram-negative rods, which included Proteus spp., Citrobacter spp., Serratia spp., and Enterobacter spp., culminating in a total of 47 (3.1%).

2.3. Isolation Rate of Pathogens by Sample Type

When split by sample type, Table 2 illustrates that E. coli (n = 754, 51%) and Enterococcus spp. (n = 498, 33.7%) were predominantly isolated in faecal samples such as cloacal swabs and faeces from poultry and other higher animals. Most of the Klebsiella spp. (n = 46, 27.2%), which included K. pneumoniae, K. aerogenes, and K. oxytoca, were isolated from animal environmental samples such as water, surface swabs, equipment, and animal pens, representing a significant faecal contamination of the environment. Furthermore, the isolation proportion of Salmonella spp. was relatively high in faecal (n = 19, 1.3%) and animal environmental samples (n = 7, 4.4%), with only one isolate (n = 1, 6.7%) from food samples like milk and eggs. Other Gram-negative rods were mostly isolated from faecal (n = 23, 1.6%) and animal environmental samples (n = 21, 12.4%).

2.4. Antibiotic Susceptibility Patterns of E. coli, Enterococcus spp., Klebsiella spp., and Salmonella spp.

The data presented in Figure 2, Figure 3, Figure 4 and Figure 5 outline the antibiotic resistance patterns for various bacterial species, specifically E. coli, Enterococcus spp., Klebsiella spp., and Salmonella spp.
The resistance patterns for E. coli (Figure 2) show a wide variation across different antibiotics, with aztreonam, nitrofurantoin, and imipenem exhibiting high susceptibility rates (98%, 95%, and 93%, respectively), indicating that these antibiotics are generally effective against E. coli.
Ceftriaxone and meropenem have susceptibility rates of 82% and 83%, respectively, while ertapenem and levofloxacin showed slightly increased resistance with 70% and 76% susceptibility. Antibiotics that showed high resistance included tetracycline at 72%, with only 26% susceptibility, followed by ampicillin (28% susceptible) and piperacillin/tazobactam (41% susceptible).
For Enterococcus spp. (Figure 3), the resistance patterns also varied significantly, with penicillin G and ampicillin presenting with high susceptibility rates of 84% and 89%, respectively. Erythromycin also showed a good susceptibility rate of 89%. Linezolid and vancomycin show moderate susceptibility rates of 50% and 53%, respectively, indicating some level of borderline resistance in the animal population. Similar to the other isolates, tetracycline had a high resistance rate of 79%, with only 19% susceptibility, and doxycycline showed a similar trend.
Klebsiella spp. (Figure 4) displayed concerning resistance patterns, despite the number of isolates being few. Ceftriaxone was highly effective with 89% susceptibility, while imipenem showed 66% susceptibility. An increasing resistance was noted with gentamicin and ciprofloxacin, which showed significant resistance, with only 40% and 52% susceptibility, respectively. Tetracycline showed the highest resistance at 70%, with only 28% susceptibility.
Salmonella spp. (Figure 5) showed a generally favourable susceptibility profile with imipenem demonstrating complete susceptibility (100%), while ampicillin, ceftriaxone, and ciprofloxacin also demonstrated high susceptibility rates (91%, 88%, and 86%, respectively).
Meropenem and trimethoprim/sulfamethoxazole exhibited moderate susceptibility rates of 86% and 79%, respectively, while tetracycline showed significant resistance with only 38% susceptibility.

2.5. Trends of Antibiotic Non-Susceptibility over Time (2020–2024)

The results in Table 3 present the trends in antibiotic non-susceptibility from 2020 to 2024, including the results from the Mann–Kendall’s Tau test. The results showed that amoxicillin/clavulanic acid demonstrated a significant (p = 0.027) upward trend in non-susceptibility from 22.2% in 2020 to 81.8% in 2024, indicating an alarming resistance over time. On the other hand, ampicillin (AMP) displayed an upward trend from 51.1% to 71.9%, suggesting growing resistance, although the variation was not statistically significant (p = 1.000). Ciprofloxacin showed a fluctuating non-susceptibility, peaking at 57.1% in 2022 but dropping to 52.4% in 2024. Imipenem remained relatively stable but with low rates of non-susceptibility over the five years, indicating consistent susceptibility levels.
The proportion of multiple resistance patterns showed that multidrug resistance (MDR) was commonly demonstrated in K. pneumoniae isolates than in E. coli and Enterococcus sp.; however, there were very few (n = 23), as shown in Table 4.

3. Discussion

This study investigated the AMR profiles of bacteria isolated from the animal health sector in Zambia. This study found that between 2020 and 2024, AMR surveillance in Zambia’s animal health sector processed 1688 samples, predominantly faecal (87.6%), with a significant rise in animal environmental samples, reflecting increased biosecurity monitoring. E. coli (50.4%) and Enterococcus spp. (30.0%) were the most common isolates, while Klebsiella spp. and Salmonella spp. were more infrequently recovered from environmental sources. E. coli showed high susceptibility to aztreonam (98%), nitrofurantoin (95%), and imipenem (93%), but low susceptibility to tetracycline (26%) and ampicillin (28%). Enterococcus spp. were largely susceptible to ampicillin (89%) and penicillin (84%) but demonstrated borderline resistance to vancomycin (53%) and linezolid (50%). Notably, amoxicillin/clavulanic acid resistance increased sharply from 22.2% to 81.8% (p = 0.027), while carbapenem susceptibility remained high across all species. These findings highlight emerging resistance to commonly used antibiotics and the need for strengthened AMS and integrated One Health surveillance.
The overwhelming majority of samples analysed were faecal (87.6%), primarily from poultry and other livestock, reflecting a surveillance bias toward enteric zoonoses like E. coli and Enterococcus spp. This is consistent with AMR studies in sub-Saharan Africa, where food animals are routinely monitored for gastrointestinal pathogens due to their public health relevance and ease of sample collection [86,87,88]. Animal environmental samples increased significantly during the study period, suggesting an expanding interest in biosecurity and the environmental dissemination of resistance genes. Such improvements are key to preventing spillover between animals, humans, and ecosystems [89]. Conversely, the underrepresentation of food (0.9%) and meat (1.5%) samples highlights underutilised opportunities for food safety and post-mortem surveillance.
Our study found that E. coli (50.4%) and Enterococcus spp. (30.0%) were most frequently isolated, reflecting their ubiquity in gut microbiota and role in AMR spread. The isolation of E. coli and Enterococcus spp. from gut microbiota in animals in Zambia has been reported in earlier studies, especially in the poultry sector [74,75,76,90,91,92]. The presence of Salmonella spp. has been reported in the animal health sector in Zambia [78,81,93,94]. The present study found that Klebsiella spp. and Salmonella spp. were more often recovered from animal environmental samples, indicating possible faecal contamination pathways. Previous studies have also demonstrated the presence of Klebsiella spp. and Salmonella spp. from domestic animals, with potential for contamination [95,96,97,98,99,100,101]. The isolation of E. coli, Enterococci spp., Salmonella spp., and Klebsiella spp. in food-producing animals indicates the need to conduct surveillance using a One Health approach because these bacteria are also isolated in humans and the environment [2,71,102,103].
The present study found that E. coli exhibited high susceptibility to aztreonam (98%), nitrofurantoin (95%), and imipenem (93%), but low susceptibility to tetracycline (26%) and ampicillin (28%). The high susceptibility to carbapenems aligns with findings from previous studies conducted in Zambia [78,79,81,104]. This observation is likely attributable to the fact that carbapenems are not routinely used in the animal health sector in Zambia, thereby limiting the selective pressure for resistance development.
Our study revealed that Enterococcus spp. demonstrated high susceptibility to ampicillin (89%) and penicillin (84%) but showed borderline resistance to vancomycin (53%) and linezolid (50%). The present findings are in contrast with a previous study performed in Zambia, which found high resistance of enterococci to ampicillin, although similar resistance to linezolid was documented [76]. Evidence of vancomycin-resistant enterococci was also reported in Tanzania across human and animal samples, indicating a One Health problem implicated by this pathogen [105]. Klebsiella spp. exhibited good susceptibility to ceftriaxone (89%) and imipenem (66%), but elevated resistance to ciprofloxacin (52%) and gentamicin (40%). A study conducted in Zambia in the human health sector found high resistance of K. pneumoniae to third-generation cephalosporins such as ceftriaxone, indicating high use of cephalosporins in the human health sector compared to the animal health sector in Zambia [106]. A recent study conducted in Lusaka, Zambia, found that K. pneumoniae was highly susceptible to carbapenems, including ertapenem and imipenem [107]. On the other hand, Salmonella spp. displayed generally high susceptibility, particularly to imipenem (100%), ceftriaxone (88%), and ciprofloxacin (86%), although reduced susceptibility was observed for tetracycline (38%). Previous studies conducted in Zambia have also demonstrated high resistance of Salmonella spp. isolated from poultry to tetracycline [78,81]. This could be due to the high use of tetracycline in the poultry sector in Zambia, especially with access without veterinary prescriptions [25,35,41,84]. The observed resistance of bacteria to antibiotics in the animal health sector in Zambia calls for urgent solutions, including the initiation of AMS programs and other innovative strategies to combat the rising AMR rates [2,71,84,108].
Our study demonstrated a significant increase in non-susceptibility to amoxicillin/clavulanic acid, rising from 22.2% in 2020 to 81.8% in 2024 (p = 0.027). Alongside this, ampicillin resistance increased from 51.1% to 71.9% over the study period, although the change was not statistically significant. Further, ciprofloxacin resistance fluctuated but remained high in some years (>50%). Furthermore, carbapenems (imipenem, meropenem) maintained low resistance, indicating preserved efficacy. Therefore, our study demonstrated evidence of the rising resistance to commonly used antibiotics, which underscores the need for strict AMS in veterinary settings. The findings highlight the need to preserve carbapenems and other critically important antimicrobials, which is crucial to prevent cross-sectoral resistance spillover. Alongside this, there is a need for targeted interventions to reduce the overuse of tetracyclines and β-lactams in livestock. These findings indicate the need to establish and strengthen AMS programs in the animal health sector in Zambia, similar to the findings and recommendations from other studies [67,71,109].
Overall, of the 1416 isolates tested, (n = 482, 34.1%) were MDR, (n = 378, 26.7%) were possible XDR, and (n = 141, 10.0%) were possible PDR, with particularly high proportions in E. coli (42.9%) and K. pneumoniae (47.8%). The results are inconsistent with other studies in Africa that revealed higher MDR prevalence among several bacterial isolates from livestock [110,111,112,113]. Even though lower, these results underscore the widespread presence of resistance across livestock-associated bacteria and the narrowing spectrum of effective antimicrobials. The findings support the urgent need for enhanced AMS, prudent drug use policies in veterinary medicine, and continued genomic surveillance to better understand the mechanisms and drivers of resistance.
The findings of the present study also indicate the need to expand sampling beyond faecal to include more animal environmental, food, and meat samples for a holistic One Health view. Alongside this, there is a need to integrate molecular typing and resistance gene detection to track AMR transmission pathways. Additionally, there is a need to strengthen data reporting to platforms like FAO InFARM and WOAH ANIMUSE for global comparability. These findings demonstrate the need to strengthen AMR surveillance in animal health, similar to findings from previous studies [61]. There is also a need to integrate AMR surveillance across the One Health sector to provide comprehensive AMR surveillance data [54,114,115].
We are aware that this study has some limitations that should be considered when interpreting the findings. First, it was based on retrospective analysis of laboratory surveillance data from selected sentinel sites, which may not fully represent AMR patterns across all regions, livestock systems, and animal species in Zambia. Second, the sample distribution was heavily skewed towards faecal samples, with limited representation of animal environmental, meat, and food samples, potentially underestimating AMR prevalence in other important reservoirs. The imbalance in sample types and the lack of proportional sampling limit this study’s ability to claim national representativeness, and as such, the findings are primarily indicative of resistance patterns within the sampled sites and sample types. Third, the dataset was restricted to phenotypic AST, with no molecular characterisation of resistance genes or strain typing, limiting the ability to determine genetic mechanisms of resistance and potential transmission pathways. The absence of molecular data prevents the identification of specific resistance genes or a definitive understanding of gene transfer. Fourth, variations in sampling intensity, diagnostic capacity, and laboratory methodologies across sites and over time may have introduced inconsistencies and bias in the results. Fifth, this study could not directly correlate AMR patterns with AMU. Finally, due to the reliance on available surveillance data, some pathogens of potential public health significance may have been missed, and temporal changes in resistance could reflect shifts in sampling or testing priorities rather than true epidemiological trends. Therefore, we recommend the need for a comprehensive, integrated surveillance system that includes both AMR and AMU data to better inform policy and intervention strategies.
The findings from this study have several important policy implications for strengthening AMR control in Zambia’s animal health sector, as shown in Table 5. The current surveillance system, which is heavily dominated by faecal sampling, should be expanded to routinely include animal environmental, food, and meat samples to better capture AMR risks across the One Health interface. The observed increase in animal environmental sampling highlights the need to institutionalise this approach within national AMR surveillance guidelines, alongside stronger farm and slaughterhouse biosecurity measures to reduce animal environmental contamination by pathogens such as Klebsiella spp. and Salmonella spp. The continued focus on priority indicators like E. coli and Enterococcus spp. is essential, but should be complemented by monitoring other relevant pathogens to broaden risk assessment. The high resistance of E. coli to tetracycline and ampicillin, coupled with the alarming rise in amoxicillin/clavulanic acid resistance, underscores the urgency of regulating veterinary antimicrobial sales, restricting growth promoter use, and promoting culture-based prescriptions. Borderline resistance in enterococci to vancomycin and linezolid signals the need to protect critically important human medicines from veterinary misuse. Preserving carbapenem efficacy by maintaining them as last-resort drugs and introducing stewardship protocols for fluoroquinolone use are vital to slowing resistance spread. Finally, investing in molecular epidemiology capacity and integrating results into global reporting platforms will enhance detection of resistance mechanisms, support targeted interventions, and align Zambia’s surveillance with international AMR control efforts.

4. Materials and Methods

4.1. Study Design and Setting

This retrospective study analysed routine laboratory data that were collected from January 2020 to December 2024 from four public and one academic animal health AMR surveillance sentinel sites across Zambia. The nationwide surveillance collects samples from all administrative provinces through a through a multistage stratified sampling technique down to districts and farms surrounding the five animal health laboratories: the Central Veterinary Laboratory Institute (CVRI) (Reference AMR laboratory), Choma Provincial Veterinary Laboratory, Chipata Provincial Veterinary Laboratory (CPVL), Mongu Provincial Veterinary Laboratory (MPVL), and the University of Zambia School of Veterinary Medicine Microbiology Laboratory (UNZA VET Lab), as shown in Figure 6. These were designated for National AMR surveillance following the FAO-ATLAS assessment that defined targets to improve national AMR surveillance systems in the food and agriculture sectors. The sentinel sites were selected based on their established capacity to perform AMR surveillance. To ensure reliable results and strengthen data validity despite routine diagnostic limitations, this study leveraged reference laboratories with advanced microbiological capacity, supported by mentorship and external quality assurance (EQA).

4.2. Study Design

Laboratory AMR surveillance data were collected retrospectively from 2020 to 2024. The samples were collected from poultry, cattle, and the animal environment. The laboratories tested samples from market-ready broiler and layer chickens (four weeks and above for broilers and at the point of lay for layers), cattle above 2 years, and environmental samples. At this stage of sampling, animals are towards the end of production, just before entering the food chain, and thus provide additional information on food safety.

4.3. Sample Type and Sample Size

This study included all five of the animal health AMR sentinel sites in Zambia. The laboratory network obtained various sample types, including cloacal swabs from poultry, faecal and milk samples from beef and dairy animals, as well as surface swabs from animal environments. The sample size for estimation for the poultry and beef samples was based on the national estimates as defined in the respective national surveillance protocols that stipulated the proportional distribution of the animal population.

4.4. Sampling Strategy

Sampling was conducted proportionally in each of the respective strata in the sampling frame, ensuring a representative distribution aligned with the overall population structure. This allowed for a better representation of the strata, depicted by the proportional share in the overall population. The surveillance considered the primary sampling unit to be a “farm”; in situations where the farm had more than one house or kraal, each one was an independent unit.

4.5. Data Collection

The data were obtained from previously isolated and identified samples, collected by trained laboratory personnel at the five sentinel sites under the supervision of the national AMR surveillance program. Sample processing was standardised across all sentinel sites, following established laboratory standard operating procedures (SOPs). The surveillance targeted organisms in healthy livestock, including E. coli, Enterococcus spp., Klebsiella spp., and Salmonella spp. These organisms had already been isolated and identified using standardised microbiological procedures, including culture and confirmation through biochemical testing [75,76,78,79,81,90,107]. All data for this compilation were derived from active surveillance of healthy, market-ready chickens (cloacal swabs, faecal samples, and eggs), cattle (faecal samples and milk), and their environments (feed, manure, litter, as well as abattoir and meat-processing surfaces, including floors, walls, and equipment). All data used for this compilation were obtained from active surveillance of healthy, market-ready chickens, cattle, and the animals’ environment. Organism selection was based on the priority pathogen list as described by the Global Antimicrobial Resistance and Use Surveillance System (GLASS) [116].

4.6. Antimicrobial Susceptibility Testing

The antibiotics used were selected according to the WHO model list of essential drugs and commonly used antibiotics in Zambia [117]. The antimicrobial classes tested included tetracyclines, penicillins, sulphonamides, macrolides, quinolones, cephalosporins, chloramphenicol, monobactams, aminoglycosides, rifamycin, nitrofurans, β-lactam inhibitors, and carbapenems. The AST testing was performed using the Kirby–Bauer disc diffusion method. The AST results were entered directly into the WHONET database, with the inbuilt Clinical Laboratory Standards Institute (CLSI) guidelines M100 used for the interpretation of AST results [118].

4.7. Quality Control and Inter-Laboratory Comparability

To ensure reliability and accuracy, quality control was carried out on media, reagents, and antibiotic disks using standard ATCC reference strains (E. coli ATCC 25922, P. aeruginosa ATCC 27853, K. pneumoniae ATCC 700603, S. aureus ATCC 25923, E. faecalis ATCC 29212). All sentinel sites followed harmonised SOPs, with results interpreted using CLSI guidelines and standardised in WHONET. Inter-laboratory comparability was maintained through participation in EQA and periodic re-testing at the national reference laboratory.

4.8. Data Analysis

Descriptive statistics were performed using WHONET 2025 and IBM SPSS version 25.0. The WHONET database was used to collect and analyse AST data, including test results of isolates, metadata, and AMR profiles. This study concentrated on comparing the rates of AMR in the bacterial isolates, determining which antibiotics are most frequently ineffective, analysing the frequency of resistance to different antibiotics, and monitoring trends over time. AMR profiles were reviewed over the five years (2020–2024), and data were visualised using charts and tables. Confidence ranges for statistical comparisons of resistance rates, including AST graphs, tables and charts, were provided by IBM SPSS version 25.0 to illustrate the resistance patterns of bacteria to different antibiotics and to ensure a clear presentation of the data.

5. Conclusions

This five-year surveillance analysis highlights a significant but addressable AMR burden in Zambia’s animal health sector. The predominance of E. coli and Enterococcus spp., combined with rising resistance to widely used antibiotics such as tetracycline and ampicillin, signals a pressing threat to animal and public health. Although susceptibility to last-resort agents like imipenem and aztreonam remains largely preserved, the notable resistance observed in pathogens such as Klebsiella spp. and Salmonella spp. underscores the urgency of regulating and rationalising AMU in livestock. This study also reveals critical surveillance gaps, including underrepresentation of animal environmental, meat, and food samples, pointing to the need for broader sample coverage. The findings provide opportunities for strengthening surveillance and stewardship programs, while further studies are needed to confirm the AMR trends and to link them to specific interventions. Embedding these measures within a comprehensive One Health framework offers the best pathway to protecting the efficacy of life-saving antibiotics and safeguarding health across human, animal, and environmental domains.

Author Contributions

Conceptualization, T.S. (Taona Sinyawa), F.G., C.C., G.M., J.B.M., J.Y.C., R.C. (Ricky Chazya), S.M. (Steward Mudenda), M.M. (Mutila Malambo) and R.C. (Roma Chilengi); methodology, T.S. (Taona Sinyawa), F.G., C.C., N.M., N.B.M., G.M., J.B.M., B.B., R.N., O.K., M.N., A.S., M.A.H., S.M. (Steward Mudenda) and C.L.; software, T.S. (Taona Sinyawa), B.B., N.M., M.N., O.K., A.S., F.M.S. and R.C. (Ricky Chazya); validation, T.S. (Taona Sinyawa), F.G., N.B.M., J.B.M., G.M., Z.M., C.L., S.M. (Steven Mubamba), C.M., S.M. (Samon Mukale), M.C. (Morreah Champo), G.D., M.M. (Mercy Mukuma), S.M. (Steward Mudenda) and R.C. (Roma Chilengi); formal analysis, T.S. (Taona Sinyawa), C.C., A.S., F.M.S., G.M., R.C. (Roma Chilengi), S.M. (Steward Mudenda) and J.B.M.; resources, F.G., G.M., J.B.M., M.M. (Mutila Malambo), F.M., T.S. (Taona Sinyawa), T.S. (Theodora Savory), J.Y.C., C.M., B.C., K.K., O.-T.S., M.C. (Mpela Chibi), S.D.M., M.A.H., F.M.S., T.S. (Theodora Savory), S.M. (Steward Mudenda) and R.C. (Ricky Chazya); data curation, T.S. (Taona Sinyawa), A.S., F.M.S., F.G., G.M., J.B.M., M.K., W.M., A.B., J.H., SM. and R.C. (Roma Chilengi); writing—original draft preparation, T.S. (Taona Sinyawa), T.S. (Theodora Savory), N.M., F.G., C.C., N.B.M., S.M. (Steward Mudenda), A.S., F.M.S., M.A.H., B.C., G.D., K.K., G.M., B.S.J.P., M.K., W.M., S.M. (Samon Mukale), A.B., J.H., B.B., O.K., M.N., R.C. (Ricky Chazya), R.N., M.M. (Mutila Malambo), Z.M., S.M. (Steven Mubamba), M.C. (Morreah Champo), M.M. (Mercy Mukuma), C.L., O.-T.S., F.M., M.C. (Mpela Chibi), S.D.M., T.S. (Theodora Savory), J.Y.C., J.B.M., C.M. and R.C. (Roma Chilengi); writing—review and editing, T.S. (Taona Sinyawa), T.S. (Theodora Savory), N.M., F.G., C.C., N.B.M., S.M. (Steward Mudenda), A.S., F.M.S., M.A.H., B.C., G.D., K.K., G.M., B.S.J.P., M.K., W.M., S.M. (Samon Mukale), A.B., J.H., B.B., O.K., M.N., R.C. (Ricky Chazya), R.N., M.M. (Mutila Malambo), Z.M., S.M. (Steven Mubamba), M.C. (Morreah Champo), M.M. (Mercy Mukuma), C.L., O.-T.S., F.M., M.C. (Mpela Chibi), S.D.M., T.S. (Theodora Savory), J.Y.C., J.B.M., C.M. and R.C. (Roma Chilengi); visualization, M.M. (Mutila Malambo), A.S., S.M. (Steward Mudenda), F.M.S., R.C. (Ricky Chazya) and B.S.J.P.; supervision, F.G., C.C., G.M., J.B.M., J.Y.C. and R.C. (Roma Chilengi); project administration, G.M., J.B.M., M.M. (Mutila Malambo), M.A.H., F.M.S., J.Y.C., S.M. (Steward Mudenda), A.S. and R.C. (Roma Chilengi); funding acquisition, F.G., J.Y.C., C.M. and R.C. (Roma Chilengi). All authors have read and agreed to the published version of the manuscript.

Funding

The Fleming Fund project-Zambia (FF 156_562 Zambia CG1) and the Food and Agriculture Organization of the United Nations (GCP/GLO/710/UK) (the views expressed in this publication are those of the author(s) and do not necessarily reflect the views or policies of the Food and Agriculture Organization of the United Nations). Additionally, this research was funded by the Zambia Multisectoral Pandemic Preparedness and Response (ZaMPPR) Project, World Health Organization, and in part by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP20wm0125008 and JP223fa627005 to YS, through the Antimicrobial Resistance Coordinating Committee (AMRCC) at the Zambia National Public Health Institute, Ministry of Health.

Institutional Review Board Statement

Ethical clearance for this study was granted by the Excellence in Research Ethics and Science (ERES) Converge Ethics Committee (Ref: 2023-Feb-002).

Informed Consent Statement

Not applicable.

Data Availability Statement

The supporting data of this manuscript can be made available on request from the corresponding authors.

Acknowledgments

We express our sincere gratitude to the Ministry of Fisheries and Livestock for granting permission to carry out this retrospective study. Our appreciation also goes to the Central Veterinary Research Institute (CVRI) and all provincial animal health laboratories involved in the National AMR Surveillance Program. We are thankful to the District Veterinary Offices and their staff for their valuable support during the surveillance activities. We are grateful to the Zambia National Public Health Institute (ZNPHI) for all the support rendered during the collection and analysis of the data, as well as report writing.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
AMCAntimicrobial Consumption
AMRAntimicrobial Resistance
AMSAntimicrobial Stewardship
AMUAntimicrobial Use
ANIMUSEANImal antiMicrobial USE global data base
FAOFood and Agriculture Organization of the United Nations
InFARMInternational FAO Antimicrobial Resistance Monitoring System
MDRMultidrug Resistance
SADCASSouthern African Development Community Accreditation Service
SPSSStatistical Package for the Social Sciences
WOAHWorld Organisation for Animal Health
ZNPHIZambia National Public Health Institute
βBeta

References

  1. Delamare-deboutteville, J.; Mohan, C.V. Antimicrobial Resistance: Preventing the Silent Pandemic in Aquatic Food Systems; WorldFish: Penang, Malaysia, 2021; Available online: https://digitalarchive.worldfishcenter.org/handle/20.500.12348/4996 (accessed on 20 December 2021).
  2. Mudenda, S.; Hakayuwa, C.M.; Lubanga, A.F.; Kasanga, M.; Daka, V.; Salachi, K.I.; Mwaba, M.; Chileshe, C.; Champo, M.; Kamayani, M.; et al. Global Antimicrobial Stewardship, Surveillance, and Infection Prevention and Control Programs: Leveraging One Health, Nanotechnology, and Artificial Intelligence to Combat Antimicrobial Resistance in a Climate-Impacted World. Pharmacol. Pharm. 2025, 16, 197–291. [Google Scholar] [CrossRef]
  3. Salam, A.; Al-Amin, Y.; Salam, M.T.; Pawar, J.S.; Akhter, N.; Rabaan, A.A.; Alqumber, M.A.A. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare 2023, 11, 1946. [Google Scholar] [CrossRef]
  4. Murray, C.J.L.; Ikuta, K.S.; Sharara, F.; Swetschinski, L.; Aguilar, G.R.; Gray, A.; Han, C.; Bisignano, C.; Rao, P.; Wool, E.; et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022, 399, 629–655. [Google Scholar] [CrossRef]
  5. Yoo, J.-H. Antimicrobial Resistance—The ‘Real’ Pandemic We Are Unaware Of, Yet Nearby. J. Korean Med. Sci. 2025, 40, e161. [Google Scholar] [CrossRef]
  6. Paneri, M.; Sevta, P. Overview of Antimicrobial Resistance: An Emerging Silent Pandemic. Glob. J. Med. Pharm. Biomed. Updat. 2023, 18, 11–13. [Google Scholar] [CrossRef]
  7. Wasan, H.; Singh, D.; Reeta, K.; Gupta, Y.K. Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward. Biology 2023, 12, 101. [Google Scholar] [CrossRef]
  8. Mendelson, M.; Sharland, M.; Mpundu, M. Antibiotic resistance: Calling time on the ‘silent pandemic’. JAC-Antimicrob. Resist. 2022, 4, dlac016. [Google Scholar] [CrossRef]
  9. FAO. The FAO Action Plan on Antimicrobial Resistance 2021–2025; FAO: Rome, Italy, 2021; pp. 1–46. [Google Scholar]
  10. Ruckert, A.; Harris, F.; Aenishaenslin, C.; Aguiar, R.; Boudreau-LeBlanc, A.; Carmo, L.P.; Labonté, R.; Lambraki, I.; Parmley, E.J.; Wiktorowicz, M.E. One Health governance principles for AMR surveillance: A scoping review and conceptual framework. Res. Dir. One Health 2024, 2, e4. [Google Scholar] [CrossRef]
  11. Abdelfattah, E.M.; Ekong, P.S.; Okello, E.; Williams, D.R.; Karle, B.M.; Rowe, J.D.; Marshall, E.S.; Lehenbauer, T.W.; Aly, S.S. 2019 Survey of Antimicrobial Drug Use and Stewardship Practices in Adult Cows on California Dairies: Post Senate Bill 27. Microorganisms 2021, 9, 1507. [Google Scholar] [CrossRef]
  12. de Kraker, M.E.A.; Stewardson, A.J.; Harbarth, S. Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? PLoS Med. 2016, 13, e1002184. [Google Scholar] [CrossRef]
  13. Tang, K.W.K.; Millar, B.C.; Moore, J.E. Antimicrobial Resistance (AMR). Br. J. Biomed. Sci. 2023, 80, 11387. [Google Scholar] [CrossRef]
  14. Stanley, D.; Batacan, R.; Bajagai, Y.S. Rapid growth of antimicrobial resistance: The role of agriculture in the problem and the solutions. Appl. Microbiol. Biotechnol. 2022, 106, 6953–6962. [Google Scholar] [CrossRef]
  15. Cuong, N.V.; Padungtod, P.; Thwaites, G.; Carrique-Mas, J.J. Antimicrobial Usage in Animal Production: A Review of the Literature with a Focus on Low- and Middle-Income Countries. Antibiotics 2018, 7, 75. [Google Scholar] [CrossRef]
  16. Hedman, H.D.; Vasco, K.A.; Zhang, L. A Review of Antimicrobial Resistance in Poultry Farming within Low-Resource Settings. Animals 2020, 10, 1264. [Google Scholar] [CrossRef]
  17. Mohsin, M.; Van Boeckel, T.P.; Saleemi, M.K.; Umair, M.; Naseem, M.N.; He, C.; Khan, A.; Laxminarayan, R. Excessive use of medically important antimicrobials in food animals in Pakistan: A five-year surveillance survey. Glob. Health Action 2019, 12, 1697541. [Google Scholar] [CrossRef]
  18. Barroga, T.R.M.; Morales, R.G.; Benigno, C.C.; Castro, S.J.M.; Caniban, M.M.; Cabullo, M.F.B.; Agunos, A.; de Balogh, K.; Dorado-Garcia, A. Antimicrobials Used in Backyard and Commercial Poultry and Swine Farms in the Philippines: A Qualitative Pilot Study. Front. Veter.-Sci. 2020, 7, 329. [Google Scholar] [CrossRef]
  19. Mulchandani, R.; Tiseo, K.; Nandi, A.; Klein, E.; Gandra, S.; Laxminarayan, R.; Van Boeckel, T. Global trends in inappropriate use of antibiotics, 2000–2021: Scoping review and prevalence estimates. BMJ Public Health 2025, 3, e002411. [Google Scholar] [CrossRef]
  20. Van Boeckel, T.P.; Brower, C.; Gilbert, M.; Grenfell, B.T.; Levin, S.A.; Robinson, T.P.; Teillant, A.; Laxminarayan, R. Global trends in antimicrobial use in food animals. Proc. Natl. Acad. Sci. USA 2015, 112, 5649–5654. [Google Scholar] [CrossRef]
  21. Van Boeckel, T.P.; Pires, J.; Silvester, R.; Zhao, C.; Song, J.; Criscuolo, N.G.; Gilbert, M.; Bonhoeffer, S.; Laxminarayan, R. Global trends in antimicrobial resistance in animals in low- and middle-income countries. Science 2019, 365, eaaw1944. [Google Scholar] [CrossRef]
  22. Booton, R.D.; Meeyai, A.; Alhusein, N.; Buller, H.; Feil, E.; Lambert, H.; Mongkolsuk, S.; Pitchforth, E.; Reyher, K.K.; Sakcamduang, W.; et al. One Health drivers of antibacterial resistance: Quantifying the relative impacts of human, animal and environmental use and transmission. One Health 2021, 12, 100220. [Google Scholar] [CrossRef]
  23. Kasimanickam, V.; Kasimanickam, M.; Kasimanickam, R. Antibiotics Use in Food Animal Production: Escalation of Antimicrobial Resistance: Where Are We Now in Combating AMR? Med. Sci. 2021, 9, 14. [Google Scholar] [CrossRef]
  24. Ahmed, S.K.; Hussein, S.; Qurbani, K.; Ibrahim, R.H.; Fareeq, A.; Mahmood, K.A.; Mohamed, M.G. Antimicrobial resistance: Impacts, challenges, and future prospects. J. Med. Surg. Public Health 2024, 2. [Google Scholar] [CrossRef]
  25. Mudenda, S.; Bumbangi, F.N.; Yamba, K.; Munyeme, M.; Malama, S.; Mukosha, M.; Hadunka, M.A.; Daka, V.; Matafwali, S.K.; Siluchali, G.; et al. Drivers of antimicrobial resistance in layer poultry farming: Evidence from high prevalence of multidrug-resistant Escherichia coli and enterococci in Zambia. Veter.-World 2023, 16, 1803–1814. [Google Scholar] [CrossRef]
  26. Norris, J.M.; Zhuo, A.; Govendir, M.; Rowbotham, S.J.; Labbate, M.; Degeling, C.; Gilbert, G.L.; Dominey-Howes, D.; Ward, M.P. Factors influencing the behaviour and perceptions of Australian veterinarians towards antibiotic use and antimicrobial resistance. PLoS ONE 2019, 14, e0223534. [Google Scholar] [CrossRef]
  27. Khan, X.; Rymer, C.; Ray, P.; Lim, R. Quantification of antimicrobial use in Fijian livestock farms. One Health 2021, 13, 100326. [Google Scholar] [CrossRef] [PubMed]
  28. Schwarz, S.; Kehrenberg, C.; Walsh, T. Use of antimicrobial agents in veterinary medicine and food animal production. Int. J. Antimicrob. Agents 2001, 17, 431–437. [Google Scholar] [CrossRef] [PubMed]
  29. Bandyopadhyay, S.; Samanta, I. Antimicrobial Resistance in Agri-Food Chain and Companion Animals as a Re-emerging Menace in Post-COVID Epoch: Low-and Middle-Income Countries Perspective and Mitigation Strategies. Front. Veter.-Sci. 2020, 7, 620. [Google Scholar] [CrossRef] [PubMed]
  30. Thakur, S.D.; Panda, A.K. Rational Use of Antimicrobials in Animal Production:A Prerequisite to Stem the Tide of Antimicrobial Resistance. Curr. Sci. 2017, 113, 1846–1857. [Google Scholar] [CrossRef]
  31. Sangeda, R.Z.; Baha, A.; Erick, A.; Mkumbwa, S.; Bitegeko, A.; Sillo, H.B.; Fimbo, A.M.; Chambuso, M.; Mbugi, E.V. Consumption Trends of Antibiotic for Veterinary Use in Tanzania: A Longitudinal Retrospective Survey From 2010-2017. Front. Trop. Dis. 2021, 2, 694082. [Google Scholar] [CrossRef]
  32. Musoke, D.; Namata, C.; Lubega, G.B.; Kitutu, F.E.; Mugisha, L.; Amir, S.; Brandish, C.; Gonza, J.; Ikhile, D.; Niyongabo, F.; et al. Access, use and disposal of antimicrobials among humans and animals in Wakiso district, Uganda: A qualitative study. J. Pharm. Policy Pr. 2021, 14, 1–12. [Google Scholar] [CrossRef]
  33. Nhung, N.T.; Chansiripornchai, N.; Carrique-Mas, J.J. Antimicrobial Resistance in Bacterial Poultry Pathogens: A Review. Front. Vet. Sci. 2017, 4, 126. [Google Scholar] [CrossRef] [PubMed]
  34. Hirwa, E.M.; Mujawamariya, G.; Shimelash, N.; Shyaka, A. Evaluation of cattle farmers’ knowledge, attitudes, and practices regarding antimicrobial use and antimicrobial resistance in Rwanda. PLoS ONE 2024, 19, e0300742. [Google Scholar] [CrossRef] [PubMed]
  35. Mudenda, S.; Mulenga, K.M.; Nyirongo, R.; Chabalenge, B.; Chileshe, C.; Daka, V.; M’kAndawire, E.; Jere, E.; Muma, J.B. Non-prescription sale and dispensing of antibiotics for prophylaxis in broiler chickens in Lusaka District, Zambia: Findings and implications on one health. JAC-Antimicrob. Resist. 2024, 6, dlae094. [Google Scholar] [CrossRef] [PubMed]
  36. Ayukekbong, J.A.; Ntemgwa, M.; Atabe, A.N. The threat of antimicrobial resistance in developing countries: Causes and control strategies. Antimicrob. Resist. Infect. Control. 2017, 6, 1–8. [Google Scholar] [CrossRef]
  37. Howard, S.J.; Catchpole, M.; Watson, J.; Davies, S.C. Antibiotic resistance: Global response needed. Lancet Infect. Dis. 2013, 13, 1001–1003. [Google Scholar] [CrossRef]
  38. Tebug, S.F.; Mouiche, M.M.M.; Abia, W.A.; Teno, G.; Tiambo, C.K.; Moffo, F.; Awah-Ndukum, J. Antimicrobial use and practices by animal health professionals in 20 sub-Saharan African countries. Prev. Veter.-Med. 2021, 186, 105212. [Google Scholar] [CrossRef]
  39. Lambrou, A.S.; Innes, G.K.; O’sUllivan, L.; Luitel, H.; Bhattarai, R.K.; Basnet, H.B.; Heaney, C.D. Policy implications for awareness gaps in antimicrobial resistance (AMR) and antimicrobial use among commercial Nepalese poultry producers. Glob. Health Res. Policy 2021, 6, 1–9. [Google Scholar] [CrossRef]
  40. Alhaji, N.; Haruna, A.; Muhammad, B.; Lawan, M.; Isola, T. Antimicrobials usage assessments in commercial poultry and local birds in North-central Nigeria: Associated pathways and factors for resistance emergence and spread. Prev. Veter.-Med. 2018, 154, 139–147. [Google Scholar] [CrossRef]
  41. Chilawa, S.; Mudenda, S.; Daka, V.; Chileshe, M.; Matafwali, S.; Chabalenge, B.; Mpundu, P.; Mufwambi, W.; Mohamed, S.; Mfune, R.L. Knowledge, Attitudes, and Practices of Poultry Farmers on Antimicrobial Use and Resistance in Kitwe, Zambia: Implications on Antimicrobial Stewardship. Open J. Anim. Sci. 2023, 13, 60–81. [Google Scholar] [CrossRef]
  42. Kuppusamy, S.; Kakarla, D.; Venkateswarlu, K.; Megharaj, M.; Yoon, Y.-E.; Lee, Y.B. Veterinary antibiotics (VAs) contamination as a global agro-ecological issue: A critical view. Agric. Ecosyst. Environ. 2018, 257, 47–59. [Google Scholar] [CrossRef]
  43. Sudatip, D.; Tiengrim, S.; Chasiri, K.; Kritiyakan, A.; Phanprasit, W.; Morand, S.; Thamlikitkul, V. One Health Surveillance of Antimicrobial Resistance Phenotypes in Selected Communities in Thailand. Antibiotics 2022, 11, 556. [Google Scholar] [CrossRef]
  44. Donado-Godoy, P.; Castellanos, R.; León, M.; Arevalo, A.; Clavijo, V.; Bernal, J.; León, D.; Tafur, M.A.; Byrne, B.A.; Smith, W.A.; et al. The Establishment of the Colombian Integrated Program for Antimicrobial Resistance Surveillance (COIPARS): A Pilot Project on Poultry Farms, Slaughterhouses and Retail Market. Zoonoses Public Health 2015, 62, 58–69. [Google Scholar] [CrossRef]
  45. da Costa, R.C.; Serrano, I.; Chambel, L.; Oliveira, M. The importance of “one health approach” to the AMR study and surveillance in Angola and other African countries. One Health 2024, 18, 100691. [Google Scholar] [CrossRef]
  46. Irfan, M.; Almotiri, A.; AlZeyadi, Z.A. Antimicrobial Resistance and Its Drivers—A Review. Antibiotics 2022, 11, 1362. [Google Scholar] [CrossRef] [PubMed]
  47. Nazir, A.; Nazir, A.; Zuhair, V.; Aman, S.; Sadiq, S.U.R.; Hasan, A.H.; Tariq, M.; Rehman, L.U.; Mustapha, M.J.; Bulimbe, D.B. The Global Challenge of Antimicrobial Resistance: Mechanisms, Case Studies, and Mitigation Approaches. Health Sci. Rep. 2025, 8, e71077. [Google Scholar] [CrossRef] [PubMed]
  48. Holmes, A.H.; Moore, L.S.P.; Sundsfjord, A.; Steinbakk, M.; Regmi, S.; Karkey, A.; Guerin, P.J.; Piddock, L.J.V. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 2016, 387, 176–187. [Google Scholar] [CrossRef] [PubMed]
  49. Belay, W.Y.; Getachew, M.; Tegegne, B.A.; Teffera, Z.H.; Dagne, A.; Zeleke, T.K.; Abebe, R.B.; Gedif, A.A.; Fenta, A.; Yirdaw, G.; et al. Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: A review. Front. Pharmacol. 2024, 15, 1444781. [Google Scholar] [CrossRef]
  50. Matheou, A.; Abousetta, A.; Pascoe, A.P.; Papakostopoulos, D.; Charalambous, L.; Panagi, S.; Panagiotou, S.; Yiallouris, A.; Filippou, C.; Johnson, E.O. Antibiotic Use in Livestock Farming: A Driver of Multidrug Resistance? Microorganisms 2025, 13, 779. [Google Scholar] [CrossRef]
  51. Urban-Chmiel, R.; Marek, A.; Stępień-Pyśniak, D.; Wieczorek, K.; Dec, M.; Nowaczek, A.; Osek, J. Antibiotic Resistance in Bacteria—A Review. Antibiotics 2022, 11, 1079. [Google Scholar] [CrossRef]
  52. Adebowale, O.; Makanjuola, M.; Bankole, N.; Olasoju, M.; Alamu, A.; Kperegbeyi, E.; Oladejo, O.; Fasanmi, O.; Adeyemo, O.; Fasina, F.O. Multi-Drug Resistant Escherichia coli, Biosecurity and Anti-Microbial Use in Live Bird Markets, Abeokuta, Nigeria. Antibiotics 2022, 11, 253. [Google Scholar] [CrossRef]
  53. Kahn, L.H. Antimicrobial resistance: A One Health perspective. Trans. R. Soc. Trop. Med. Hyg. 2017, 111, 255–260. [Google Scholar] [CrossRef]
  54. Collineau, L.; Bourély, C.; Rousset, L.; Berger-Carbonne, A.; Ploy, M.-C.; Pulcini, C.; Colomb-Cotinat, M. Towards One Health surveillance of antibiotic resistance: Characterisation and mapping of existing programmes in humans, animals, food and the environment in France, 2021. Eurosurveillance 2023, 28, 2200804. [Google Scholar] [CrossRef] [PubMed]
  55. Ye, Z.; Li, M.; Jing, Y.; Liu, K.; Wu, Y.; Peng, Z. What Are the Drivers Triggering Antimicrobial Resistance Emergence and Spread? Outlook from a One Health Perspective. Antibiotics 2025, 14, 543. [Google Scholar] [CrossRef]
  56. Samreen Ahmad, I.; Malak, H.A.; Abulreesh, H.H. Environmental Antimicrobial Resistance and Its Drivers: A Potential Threat to Public Health. J. Glob. Antimicrob. Resist. 2021, 27, 101–111. [Google Scholar] [CrossRef]
  57. Davies, B.; Erlacher-Vindel, E.; Kuribrena, M.A.; Gochez, D.; Jeannin, M.; Magongo, M.; Valsson, O.; Yugueros-Marcos, J. Antimicrobial use in animals: A journey towards integrated surveillance. Rev. Sci. Tech. l’OIE 2023, 42, 201–209. [Google Scholar] [CrossRef]
  58. World Organization for Animal Health. ANIMUSE: Monitoring Antimicrobial Use in Animals; World Organization for Animal Health: Paris, France, 2023. [Google Scholar]
  59. Devreese, M.; Anadon, A.; Reeve-Johnson, L. The availability and use of antimicrobial agents. J. Veter.-Pharmacol. Ther. 2023, 46, 4–5. [Google Scholar] [CrossRef]
  60. Food and Agriculture Organization of the United Nations. Monitoring and Surveillance of Antimicrobial Resistance in Bacteria from Healthy Food Animals Intended for Consumption; Food and Agriculture Organization of the United Nations: Rome, Italy, 2019; Volume 1, ISBN 9788589629768. [Google Scholar]
  61. Queenan, K.; Häsler, B.; Rushton, J. A One Health approach to antimicrobial resistance surveillance: Is there a business case for it? Int. J. Antimicrob. Agents 2016, 48, 422–427. [Google Scholar] [CrossRef] [PubMed]
  62. Sandberg, M.; Hesp, A.; Aenishaenslin, C.; Bordier, M.; Bennani, H.; Bergwerff, U.; Chantziaras, I.; De Meneghi, D.; Ellis-Iversen, J.; Filippizi, M.-E.; et al. Assessment of Evaluation Tools for Integrated Surveillance of Antimicrobial Use and Resistance Based on Selected Case Studies. Front. Veter.-Sci. 2021, 8, 663. [Google Scholar] [CrossRef] [PubMed]
  63. Oberin, M.; Badger, S.; Faverjon, C.; Cameron, A.; Bannister-Tyrrell, M. Electronic information systems for One Health surveillance of antimicrobial resistance: A systematic scoping review. BMJ Glob. Health 2022, 7, e007388. [Google Scholar] [CrossRef]
  64. Schrijver, R.; Stijntjes, M.; Rodríguez-Baño, J.; Tacconelli, E.; Rajendran, N.B.; Voss, A. Review of antimicrobial resistance surveillance programmes in livestock and meat in EU with focus on humans. Clin. Microbiol. Infect. 2018, 24, 577–590. [Google Scholar] [CrossRef]
  65. Agunos, A.; Gow, S.P.; Léger, D.F.; Carson, C.A.; Deckert, A.E.; Bosman, A.L.; Loest, D.; Irwin, R.J.; Reid-Smith, R.J. Antimicrobial Use and Antimicrobial Resistance Indicators—Integration of Farm-Level Surveillance Data From Broiler Chickens and Turkeys in British Columbia, Canada. Front. Veter.-Sci. 2019, 6, 131. [Google Scholar] [CrossRef]
  66. Robbins, S.N.; Goggs, R.; Kraus-Malett, S.; Goodman, L. Effect of institutional antimicrobial stewardship guidelines on prescription of critically important antimicrobials for dogs and cats. J. Veter.-Intern. Med. 2024, 38, 1706–1717. [Google Scholar] [CrossRef] [PubMed]
  67. Allerton, F.; Russell, J. Antimicrobial stewardship in veterinary medicine: A review of online resources. JAC-Antimicrob. Resist. 2023, 5, dlad058. [Google Scholar] [CrossRef]
  68. Lakoh, S.; Bawoh, M.; Lewis, H.; Jalloh, I.; Thomas, C.; Barlatt, S.; Jalloh, A.; Deen, G.F.; Russell, J.B.W.; Kabba, M.S.; et al. Establishing an Antimicrobial Stewardship Program in Sierra Leone: A Report of the Experience of a Low-Income Country in West Africa. Antibiotics 2023, 12, 424. [Google Scholar] [CrossRef]
  69. Hibbard, R.; Mendelson, M.; Page, S.W.; Ferreira, J.P.; Pulcini, C.; Paul, M.C.; Faverjon, C. Antimicrobial stewardship: A definition with a One Health perspective. Npj Antimicrob. Resist. 2024, 2, 15. [Google Scholar] [CrossRef]
  70. Musoke, D.; Kitutu, F.E.; Mugisha, L.; Amir, S.; Brandish, C.; Ikhile, D.; Kajumbula, H.; Kizito, I.M.; Lubega, G.B.; Niyongabo, F.; et al. A One Health Approach to Strengthening Antimicrobial Stewardship in Wakiso District, Uganda. Antibiotics 2020, 9, 764. [Google Scholar] [CrossRef]
  71. Mudenda, S.; Chabalenge, B.; Daka, V.; Mfune, R.L.; Salachi, K.I.; Mohamed, S.; Mufwambi, W.; Kasanga, M.; Matafwali, S.K. Global Strategies to Combat Antimicrobial Resistance: A One Health Perspective. Pharmacol. Pharm. 2023, 14, 271–328. [Google Scholar] [CrossRef]
  72. Zambia National Public Health Institute. Multi-Sectoral National Action Plan on Antimicrobial Resistance; Zambia National Public Health Institute: Lusaka, Zambia, 2017; Available online: https://www.afro.who.int/publications/multi-sectoral-national-action-plan-antimicrobial-resistance-2017-2027 (accessed on 20 December 2021).
  73. Zambia National Public Health Institute. Zambia’s Integrated Antimicrobial Resistance Surveillance Framework; Zambia National Public Health Institute: Lusaka, Zambia, 2020; Available online: https://www.afro.who.int/publications/zambias-integrated-antimicrobial-resistance-surveillance-framework (accessed on 20 December 2021).
  74. Sinyawa, T.; Shawa, M.; Muuka, G.M.; Goma, F.; Fandamu, P.; Chizimu, J.Y.; Khumalo, C.S.; Mulavu, M.; Ngoma, M.; Chambaro, H.M.; et al. Antimicrobial Use Survey and Detection of ESBL-Escherichia coli in Commercial and Medium-/Small-Scale Poultry Farms in Selected Districts of Zambia. Antibiotics 2024, 13, 467. [Google Scholar] [CrossRef]
  75. Chileshe, C.; Shawa, M.; Phiri, N.; Ndebe, J.; Khumalo, C.S.; Nakajima, C.; Kajihara, M.; Higashi, H.; Sawa, H.; Suzuki, Y.; et al. Detection of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteriaceae from Diseased Broiler Chickens in Lusaka District, Zambia. Antibiotics 2024, 13, 259. [Google Scholar] [CrossRef] [PubMed]
  76. Mudenda, S.; Matafwali, S.K.; Malama, S.; Munyeme, M.; Yamba, K.; Katemangwe, P.; Siluchali, G.; Mainda, G.; Mukuma, M.; Bumbangi, F.N.; et al. Prevalence and antimicrobial resistance patterns of Enterococcus species isolated from laying hens in Lusaka and Copperbelt provinces of Zambia: A call for AMR surveillance in the poultry sector. JAC-Antimicrob. Resist. 2022, 4, dlac126. [Google Scholar] [CrossRef] [PubMed]
  77. Chishimba, K.; Hang’oMbe, B.M.; Muzandu, K.; Mshana, S.E.; Matee, M.I.; Nakajima, C.; Suzuki, Y. Detection of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Market-Ready Chickens in Zambia. Int. J. Microbiol. 2016, 2016, 5275724. [Google Scholar] [CrossRef] [PubMed]
  78. Phiri, N.; Mainda, G.; Mukuma, M.; Sinyangwe, N.N.; Banda, L.J.; Kwenda, G.; Muonga, E.M.; Flavien, B.N.; Mwansa, M.; Yamba, K.; et al. Antibiotic-resistant Salmonella species and Escherichia coli in broiler chickens from farms, abattoirs, and open markets in selected districts of Zambia. J. Epidemiol. Res. 2020, 6, 13. [Google Scholar] [CrossRef]
  79. Mwansa, M.; Mukuma, M.; Mulilo, E.; Kwenda, G.; Mainda, G.; Yamba, K.; Bumbangi, F.N.; Muligisa-Muonga, E.; Phiri, N.; Silwamba, I.; et al. Determination of antimicrobial resistance patterns of Escherichia coli isolates from farm workers in broiler poultry production and assessment of antibiotic resistance awareness levels among poultry farmers in Lusaka, Zambia. Front. Public Health 2023, 10, 998860. [Google Scholar] [CrossRef]
  80. Kabali, E.; Pandey, G.S.; Munyeme, M.; Kapila, P.; Mukubesa, A.N.; Ndebe, J.; Muma, J.B.; Mubita, C.; Muleya, W.; Muonga, E.M.; et al. Identification of Escherichia coli and Related Enterobacteriaceae and Examination of Their Phenotypic Antimicrobial Resistance Patterns: A Pilot Study at A Wildlife–Livestock Interface in Lusaka, Zambia. Antibiotics 2021, 10, 238. [Google Scholar] [CrossRef]
  81. Muligisa-Muonga, E.; Mainda, G.; Mukuma, M.; Kwenda, G.; Hang’oMbe, B.; Flavien, B.N.; Phiri, N.; Mwansa, M.; Munyeme, M.; Muma, J.B. Antimicrobial resistance of Escherichiacoli and Salmonella isolated from retail broiler chicken carcasses in Zambia. J. Epidemiol. Res. 2020, 6, 35. [Google Scholar] [CrossRef]
  82. Phiri, B.S.; Hang’OMbe, B.M.; Mulenga, E.; Mubanga, M.; Maurischat, S.; Wichmann-Schauer, H.; Schaarschmidt, S.; Fetsch, A. Prevalence and diversity of Staphylococcus aureus in the Zambian dairy value chain: A public health concern. Int. J. Food Microbiol. 2022, 375, 109737. [Google Scholar] [CrossRef]
  83. Samutela, M.T.; Phiri, B.S.J.; Simulundu, E.; Kwenda, G.; Moonga, L.; Bwalya, E.C.; Muleya, W.; Nyirahabimana, T.; Yamba, K.; Kainga, H.; et al. Antimicrobial Susceptibility Profiles and Molecular Characterisation of Staphylococcus aureus from Pigs and Workers at Farms and Abattoirs in Zambia. Antibiotics 2022, 11, 844. [Google Scholar] [CrossRef] [PubMed]
  84. Mudenda, S.; Malama, S.; Munyeme, M.; Hang’ombe, B.M.; Mainda, G.; Kapona, O.; Mukosha, M.; Yamba, K.; Bumbangi, F.N.; Mfune, R.L.; et al. Awareness of Antimicrobial Resistance and Associated Factors among Layer Poultry Farmers in Zambia: Implications for Surveillance and Antimicrobial Stewardship Programs. Antibiotics 2022, 11, 383. [Google Scholar] [CrossRef]
  85. Mudenda, S.; Mufwambi, W.; Mohamed, S. The Burden of Antimicrobial Resistance in Zambia, a Sub-Saharan African Country: A One Health Review of the Current Situation, Risk Factors, and Solutions. Pharmacol. Pharm. 2024, 15, 403–465. [Google Scholar] [CrossRef]
  86. Donkor, E.S.; Odoom, A.; Osman, A.-H.; Darkwah, S.; Kotey, F.C.N. A Systematic Review on Antimicrobial Resistance in Ghana from a One Health Perspective. Antibiotics 2024, 13, 662. [Google Scholar] [CrossRef] [PubMed]
  87. O’Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations; The Review on Antimicrobial Resistance: London, UK, 2016; Available online: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (accessed on 20 December 2021).
  88. Tiseo, K.; Huber, L.; Gilbert, M.; Robinson, T.P.; Van Boeckel, T.P. Global Trends in Antimicrobial Use in Food Animals from 2017 to 2030. Antibiotics 2020, 9, 918. [Google Scholar] [CrossRef]
  89. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022; World Health Organization: Geneva, Switzerland, 2022; ISBN 9789240005587. Available online: https://www.who.int/publications/i/item/9789240062702 (accessed on 20 December 2021).
  90. Mwikuma, G.; Kainga, H.; Kallu, S.A.; Nakajima, C.; Suzuki, Y.; Hang’ombe, B.M. Determination of the Prevalence and Antimicrobial Resistance of Enterococcus faecalis and Enterococcus faecium Associated with Poultry in Four Districts in Zambia. Antibiotics 2023, 12, 657. [Google Scholar] [CrossRef] [PubMed]
  91. Kasanga, M.; Shempela, D.M.; Daka, V.; Mwikisa, M.J.; Sikalima, J.; Chanda, D.; Mudenda, S. Antimicrobial resistance profiles of Escherichia coli isolated from clinical and environmental samples: Findings and implications. JAC-Antimicrob. Resist. 2024, 6, dlae061. [Google Scholar] [CrossRef]
  92. Kasanga, M.; Kwenda, G.; Wu, J.; Kasanga, M.; Mwikisa, M.J.; Chanda, R.; Mupila, Z.; Yankonde, B.; Sikazwe, M.; Mwila, E.; et al. Antimicrobial Resistance Patterns and Risk Factors Associated with ESBL-Producing and MDR Escherichia coli in Hospital and Environmental Settings in Lusaka, Zambia: Implications for One Health, Antimicrobial Stewardship and Surveillance Systems. Microorganisms 2023, 11, 1951. [Google Scholar] [CrossRef]
  93. Songe, M.M.; Hang’ombe, B.M.; Knight-Jones, T.J.D.; Grace, D. Antimicrobial Resistant Enteropathogenic Escherichia coli and Salmonella spp. in Houseflies Infesting Fish in Food Markets in Zambia. Int. J. Environ. Res. Public Health 2016, 14, 21. [Google Scholar] [CrossRef]
  94. Kaonga, N.; Hang’ombe, B.M.; Lupindu, A.M.; Hoza, A.S. Detection of CTX-M-Type Extended-Spectrum Beta-Lactamase Producing Salmonella Typhimurium in Commercial Poultry Farms in Copperbelt Province, Zambia. Ger. J. Veter.-Res. 2021, 1, 27–34. [Google Scholar] [CrossRef]
  95. Ribeiro, M.G.; de Morais, A.B.C.; Alves, A.C.; Bolaños, C.A.D.; de Paula, C.L.; Portilho, F.V.R.; Júnior, G.d.N.; Lara, G.H.B.; Martins, L.d.S.A.; Moraes, L.S.; et al. Klebsiella-induced infections in domestic species: A case-series study in 697 animals (1997–2019). Braz. J. Microbiol. 2022, 53, 455–464. [Google Scholar] [CrossRef] [PubMed]
  96. Araújo, S.; Silva, V.; Quintelas, M.; Martins, Â.; Igrejas, G.; Poeta, P. From soil to surface water: Exploring Klebsiella ‘s clonal lineages and antibiotic resistance odyssey in environmental health. BMC Microbiol. 2025, 25, 97. [Google Scholar] [CrossRef]
  97. Rahman, M.; Alam, M.-U.; Luies, S.K.; Kamal, A.; Ferdous, S.; Lin, A.; Sharior, F.; Khan, R.; Rahman, Z.; Parvez, S.M.; et al. Contamination of Fresh Produce with Antibiotic-Resistant Bacteria and Associated Risks to Human Health: A Scoping Review. Int. J. Environ. Res. Public Health 2022, 19, 360. [Google Scholar] [CrossRef]
  98. Abbas, R.; Chakkour, M.; El Dine, H.Z.; Obaseki, E.F.; Obeid, S.T.; Jezzini, A.; Ghssein, G.; Ezzeddine, Z. General Overview of Klebsiella pneumonia: Epidemiology and the Role of Siderophores in Its Pathogenicity. Biology 2024, 13, 78. [Google Scholar] [CrossRef]
  99. Popa, G.L.; Popa, M.I. Salmonella spp. infection—A continuous threat worldwide. GERMS 2021, 11, 88–96. [Google Scholar] [CrossRef]
  100. Adzitey, F.; Tibile, B.A.; Addy, F.; Adu-Bonsu, G.; Amagloh, A.S.A.; Noyoro, E.J.; Tsigbey, V.E. Occurrence, antimicrobial susceptibility and genomic characterization of Salmonella enterica isolated from milk and related sources. Cogent Food Agric. 2025, 11, 2486330. [Google Scholar] [CrossRef]
  101. Galán-Relaño, Á.; Díaz, A.V.; Lorenzo, B.H.; Gómez-Gascón, L.; Rodríguez, M.Á.M.; Jiménez, E.C.; Rodríguez, F.P.; Márquez, R.J.A. Salmonella and Salmonellosis: An Update on Public Health Implications and Control Strategies. Animals 2023, 13, 3666. [Google Scholar] [CrossRef] [PubMed]
  102. McEwen, S.A.; Collignon, P.J. Antimicrobial Resistance: A One Health Perspective. Microbiol. Spectr. 2018, 6, 521–547. [Google Scholar] [CrossRef] [PubMed]
  103. Ariyawansa, S.; Gunawardana, K.N.; Hapudeniya, M.M.; Manelgamage, N.J.; Karunarathne, C.R.; Madalagama, R.P.; Ubeyratne, K.H.; Wickramasinghe, D.; Tun, H.M.; Wu, P.; et al. One Health Surveillance of Antimicrobial Use and Resistance: Challenges and Successes of Implementing Surveillance Programs in Sri Lanka. Antibiotics 2023, 12, 446. [Google Scholar] [CrossRef] [PubMed]
  104. Mudenda, S.; Malama, S.; Munyeme, M.; Matafwali, S.K.; Kapila, P.; Katemangwe, P.; Mainda, G.; Mukubesa, A.N.; Hadunka, M.A.; Muma, J.B. Antimicrobial resistance profiles of Escherichia coli isolated from laying hens in Zambia: Implications and significance on one health. JAC-Antimicrob. Resist. 2023, 5, dlad060. [Google Scholar] [CrossRef]
  105. Madoshi, B.; Mtambo, M.; Muhairwa, A.; Lupindu, A.; Olsen, J. Isolation of vancomycin-resistant Enterococcus from apparently healthy human animal attendants, cattle and cattle wastes in Tanzania. J. Appl. Microbiol. 2018, 124, 1303–1310. [Google Scholar] [CrossRef]
  106. Yamba, K.; Chizimu, J.Y.; Chanda, R.; Mpundu, M.; Samutela, M.T.; Chanda, D.; Mudenda, S.; Finjika, M.; Chansa, B.N.; Siame, A.; et al. Antibiotic resistance profiles in Gram-negative bacteria causing bloodstream and urinary tract infections in paediatric and adult patients in Ndola District, Zambia, 2020–2021. Infect. Prev. Pr. 2025, 7, 100462. [Google Scholar] [CrossRef]
  107. Henry, M.C.; Geoffrey, K.; Mulemba, T.S.; Baron, Y.; Nawa, M.; Ruth, N.; Mildred, Z.; Sankananji, N.; Anita, K.; Amon, S.; et al. Antimicrobial resistance of clinical and environmental klebsiella pneumoniae isolates in selected areas of Lusaka, Zambia. Afr. J. Microbiol. Res. 2025, 19, 72–82. [Google Scholar] [CrossRef]
  108. Mudenda, S.; Mukosha, M.; Godman, B.; Fadare, J.; Malama, S.; Munyeme, M.; Hikaambo, C.N.; Kalungia, A.C.; Hamachila, A.; Kainga, H.; et al. Knowledge, Attitudes, and Practices of Community Pharmacy Professionals on Poultry Antibiotic Dispensing, Use, and Bacterial Antimicrobial Resistance in Zambia: Implications on Antibiotic Stewardship and WHO AWaRe Classification of Antibiotics. Antibiotics 2022, 11, 1210. [Google Scholar] [CrossRef]
  109. Lagana, D.M.; Taylor, D.D.; Walter, E.J.S. Advancing antimicrobial stewardship in companion animal veterinary medicine: A qualitative study on perceptions and solutions to a One Health problem. J. Am. Veter.-Med. Assoc. 2023, 261, 1200–1207. [Google Scholar] [CrossRef]
  110. Azabo, R.R.; Mshana, S.E.; Matee, M.I.; Kimera, S.I. Antimicrobial Resistance Pattern of Escherichia coli Isolates from Small Scale Dairy Cattle in Dar es Salaam, Tanzania. Animals 2022, 12, 1853. [Google Scholar] [CrossRef] [PubMed]
  111. Munengwa, A.; Nation, C.; Alban, M.; Lenin, D. Susceptibility profile of Zimbabwean livestock fecal Escherichia coli isolates to veterinary antibiotics: Implications for standardization of antimicrobial resistance surveillance in livestock production. Aceh J. Anim. Sci. 2022, 7, 34–40. [Google Scholar] [CrossRef]
  112. Azabo, R.; Dulle, F.; Mshana, S.E. Antimicrobial Use in Cattle and Poultry Production on Occurrence of Multidrug Resistant Escherichia Coli. A Systematic Review with Focus on Sub-Saharan Africa. Front. Vet. Sci. 2022, 9, 1000457. [Google Scholar] [CrossRef]
  113. Founou, L.L.; Amoako, D.G.; Founou, R.C.; Essack, S.Y. Antibiotic Resistance in Food Animals in Africa: A Systematic Review and Meta-Analysis. Microb. Drug Resist. 2018, 24, 648–665. [Google Scholar] [CrossRef] [PubMed]
  114. Rüegg, S.R.; Antoine-Moussiaux, N.; Aenishaenslin, C.; Alban, L.; Bordier, M.; Bennani, H.; Schauer, B.; Arnold, J.-C.; Gabain, I.; Sauter-Louis, C.; et al. Guidance for evaluating integrated surveillance of antimicrobial use and resistance. CABI One Health 2022, 2022, ohcs20220007. [Google Scholar] [CrossRef]
  115. Aenishaenslin, C.; Häsler, B.; Ravel, A.; Parmley, E.J.; Mediouni, S.; Bennani, H.; Stärk, K.D.C.; Buckeridge, D.L. Evaluating the Integration of One Health in Surveillance Systems for Antimicrobial Use and Resistance: A Conceptual Framework. Front. Veter.-Sci. 2021, 8, 611931. [Google Scholar] [CrossRef]
  116. World Health Organization. GLASS Methodology for Surveillance of National Antimicrobial Consumption; World Health Organization: Geneva, Switzerland, 2020; Available online: https://www.who.int/publications/i/item/9789240012639 (accessed on 20 December 2021).
  117. World Health Organization. WHO Bacterial Priority Pathogens List 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance; World Health Organization: Geneva, Switzerland, 2024; Available online: https://iris.who.int/bitstream/handle/10665/376776/9789240093461-eng.pdf?sequence=1 (accessed on 20 December 2021).
  118. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, Thirtieth Edition: M100. Available online: https://unitedvrg.com/2021/05/20/m100-performance-standards-for-antimicrobial-susceptibility-testing-30th-edition-2020-pdf/ (accessed on 26 August 2021).
Figure 1. Profile of microorganisms isolated from different samples in animal health over the five years (2020 to 2024).
Figure 1. Profile of microorganisms isolated from different samples in animal health over the five years (2020 to 2024).
Antibiotics 14 01102 g001
Figure 2. Antimicrobial susceptibility patterns of E. coli over time (2020 to 2024). ATM—aztreonam, IMP—imipenem, NIT—nitrofurantoin, MEM—meropenem, CRO—ceftriaxone, ETP—ertapenem, LVX—levofloxacin, CHL—chloramphenicol, AMK—amikacin, CIP—ciprofloxacin, AMC—amoxicillin—clavulanic acid, GEN—gentamicin, FEP—cefepime, CTX—cefotaxime, SXT—sulfamethoxazole/trimethoprim, AMP—ampicillin, TZP—piperacillin–tazobactam, TET—tetracycline. S—susceptible, I—intermediate, R—resistant.
Figure 2. Antimicrobial susceptibility patterns of E. coli over time (2020 to 2024). ATM—aztreonam, IMP—imipenem, NIT—nitrofurantoin, MEM—meropenem, CRO—ceftriaxone, ETP—ertapenem, LVX—levofloxacin, CHL—chloramphenicol, AMK—amikacin, CIP—ciprofloxacin, AMC—amoxicillin—clavulanic acid, GEN—gentamicin, FEP—cefepime, CTX—cefotaxime, SXT—sulfamethoxazole/trimethoprim, AMP—ampicillin, TZP—piperacillin–tazobactam, TET—tetracycline. S—susceptible, I—intermediate, R—resistant.
Antibiotics 14 01102 g002
Figure 3. Antimicrobial susceptibility patterns of Enterococcus spp. Over time (2020 to 2024). LVX—levofloxacin, NIT—nitrofurantoin, LNZ—linezolid, DOX—doxycycline, CHL—chloramphenicol, PEN—penicillin, AMP—ampicillin, CIP—ciprofloxacin, VAN—vancomycin, RIF—rifampicin, ERY—erythromycin. S—susceptible, I—intermediate, R—resistant.
Figure 3. Antimicrobial susceptibility patterns of Enterococcus spp. Over time (2020 to 2024). LVX—levofloxacin, NIT—nitrofurantoin, LNZ—linezolid, DOX—doxycycline, CHL—chloramphenicol, PEN—penicillin, AMP—ampicillin, CIP—ciprofloxacin, VAN—vancomycin, RIF—rifampicin, ERY—erythromycin. S—susceptible, I—intermediate, R—resistant.
Antibiotics 14 01102 g003
Figure 4. Antimicrobial susceptibility patterns of Klebsiella spp. over time (2020 to 2024). IMP—imipenem, CIP—ciprofloxacin, CHL—chloramphenicol, GEN—gentamicin, CRO—ceftriaxone, FEP—cefepime, SXT—sulfamethoxazole/trimethoprim, TET—tetracycline. S—susceptible, I—intermediate, R—resistant.
Figure 4. Antimicrobial susceptibility patterns of Klebsiella spp. over time (2020 to 2024). IMP—imipenem, CIP—ciprofloxacin, CHL—chloramphenicol, GEN—gentamicin, CRO—ceftriaxone, FEP—cefepime, SXT—sulfamethoxazole/trimethoprim, TET—tetracycline. S—susceptible, I—intermediate, R—resistant.
Antibiotics 14 01102 g004
Figure 5. Antimicrobial susceptibility patterns of Salmonella spp. over time (2020 to 2024). CRO—ceftriaxone, CTX—cefotaxime, IMP—imipenem, MEM—meropenem, AZM—azithromycin, CHL—chloramphenicol, TET—tetracycline, SXT—sulfamethoxazole/trimethoprim, AMP—ampicillin, CIP—ciprofloxacin. S—susceptible, I—intermediate, R—resistant.
Figure 5. Antimicrobial susceptibility patterns of Salmonella spp. over time (2020 to 2024). CRO—ceftriaxone, CTX—cefotaxime, IMP—imipenem, MEM—meropenem, AZM—azithromycin, CHL—chloramphenicol, TET—tetracycline, SXT—sulfamethoxazole/trimethoprim, AMP—ampicillin, CIP—ciprofloxacin. S—susceptible, I—intermediate, R—resistant.
Antibiotics 14 01102 g005
Figure 6. Map showing the districts from which samples were collected during the study period.
Figure 6. Map showing the districts from which samples were collected during the study period.
Antibiotics 14 01102 g006
Table 1. Total samples cultured between 2020 and 2024.
Table 1. Total samples cultured between 2020 and 2024.
Sample TypeTotal20202021202220232024p Value *
n (%)n (%)n (%)n (%)n (%)n (%)
Faecal1478 (87.6%)524 (98.5%)336 (92.0%)219 (92.0%)255 (85.6%)144 (56.5%)0.086
Animal environmental169 (10.0%)0 (0%)5 (1.4%)18 (7.6%)41 (13.8%)105 (41.2%)0.027
Meat26 (1.5%)0 (0%)24 (6.6%)0 (0%)2 (0.6%)0 (0%)1.000
Food15 (0.9%)8 (1.5%)0 (0%)1 (0.4%)0 (0%)6 (2.3%)1.000
Total16885323652382982550.086
* Mann–Kendall Tau’s p-value for trends over five years. Note: Some sample types recorded zero in 2020 and 2021, possibly due to COVID-19, which caused a reduction in sample throughput.
Table 2. Bacterial Isolate Profiles by Sample Type.
Table 2. Bacterial Isolate Profiles by Sample Type.
OrganismFaecal (n = 1478)Animal Environmental (n = 169)Meat (n = 26)Food (n = 15)Total (n = 1688)
n%n%n%n%n%
Escherichia coli75451.0%7745.6%830.8%1173.3%85050.4%
Enterococcus spp.49833.7%63.6%311.5%00.0%50730.0%
Klebsiella spp.130.9%4627.2%00.0%00.0%593.5%
Other GNRs231.6%2112.4%27.7%16.7%472.8%
Salmonella spp.191.3%74.1%00.0%16.7%271.6%
Non-enterococcal Strep Group D60.4%00.0%00.0%00.0%60.4%
Staphylococcus aureus10.1%00.0%27.7%213.3%50.3%
CONS00.0%00.0%27.7%00.0%20.1%
Table 3. Trends of antibiotic non-susceptibility over time (2020–2024) and the Mann–Kendall Tau’s test of trends.
Table 3. Trends of antibiotic non-susceptibility over time (2020–2024) and the Mann–Kendall Tau’s test of trends.
AntibioticsPeriod: 2020–2024Mann–Kendall’s Tau Test
20202021202220232024
%NS%NS%NS%NS%NSKendall’s Taup-ValueSen’s Slope
AMC %NS22.226.836.948.881.81.0000.02711.450
AMP %NS51.151.24944.771.90.0001.000−0.475
CHL %NS23.317.921.227.725.50.4000.4621.808
CIP %NS35.725.757.140.552.40.4000.4625.788
FEP %NS0.65.214.37.728.30.8000.0866.888
CTX %NS31.320.944.487.535.50.4000.4625.708
CRO %NS7.58.325.51448.80.8000.0869.663
CAZ %NS5.52.622.729.444.10.8000.08610.175
ERY %NS86.575.286.668.376.7−0.2000.806−2.950
GEN %NS44495840.542.5−0.2000.806−0.771
IPM %NS4.317.99.19.210.50.4000.4621.000
LNZ %NS28.120.535.423.220.8−0.2000.806−1.729
MEM %NS010.133.320.339.10.8000.0869.721
TCY %NS80.972.179.559.779.9−0.2000.806−0.475
SXT %NS5052.745.248.156.20.2000.8061.358
VAN %NS45.135.383.538.681.80.2000.8065.413
LVX %NS015.722.176.9100.4000.4628.725
AMK %NS30.8010073.8600.2000.80610.817
Table 4. Proportion of multidrug resistance patterns of E. coli, Enterococcus spp. and Klebsiella spp. isolated from animal health sources.
Table 4. Proportion of multidrug resistance patterns of E. coli, Enterococcus spp. and Klebsiella spp. isolated from animal health sources.
OrganismNumber of IsolatesMDRPossible XDRPossible PDR
E. coli850411 (48.4%)313 (36.8%)110 (12.9%)
Enterococcus spp.50760 (11.8%)54 (10.7%)21 (4.1%)
Klebsiella spp.5911 (18.6%)11 (18.6%)10 (16.9%)
Total1416482378141
Table 5. Policy implications of AMR surveillance findings in Zambia’s animal health sector (2020–2024).
Table 5. Policy implications of AMR surveillance findings in Zambia’s animal health sector (2020–2024).
Key FindingPolicy ImplicationProposed ActionResponsible Stakeholders
High proportion of faecal samples (87.6%) and limited animal environmental, food, and meat samplingSurveillance scope is narrow, potentially missing AMR sources in the animal environment and food chainExpand sentinel site protocols to include routine animal environmental, meat, and food sample collection to support One Health surveillanceMinistry of Fisheries and Livestock (MFL); Zambia National Public Health Institute (ZNPHI); Ministry of Health (MoH); FAO
Significant increase in animal environmental samples (p = 0.027)Growing recognition of animal environmental AMR risksInstitutionalise animal environmental sampling in AMR surveillance guidelines and integrate with environmental health monitoringMFL; ZNPHI; Zambia Environmental Management Agency (ZEMA)
E. coli and Enterococcus spp. dominate isolatesThese pathogens are priority AMR indicators and can spread resistance genesMaintain focus on these species while adding other relevant pathogens for comprehensive risk profilingMFL; MoH; FAO; WOAH
Klebsiella spp. and Salmonella spp. are more prevalent in environmental samplesEnvironmental contamination may be a significant reservoir for resistant pathogensStrengthen farm-level and slaughterhouse biosecurity measures; enforce waste management standardsMFL; Local Authorities; ZEMA; Food Safety Agencies
Low susceptibility of E. coli to tetracycline (26%) and ampicillin (28%)Overuse of common antimicrobials in veterinary practice is likely contributing to resistanceRegulate veterinary antimicrobial sales; implement restrictions on growth-promoter use; encourage alternatives to antibioticsVeterinary Council of Zambia (VCZ); MFL; Zambia Medicines Regulatory Authority (ZAMRA)
Borderline resistance in Enterococcus spp. to vancomycin (53%) and linezolid (50%)Potential emergence of resistance to critically important human medicinesEnforce strict controls on veterinary use of critical antimicrobials; introduce a national “protected list” of antibioticsMoH; MFL; ZAMRA; VCZ
Increasing resistance to amoxicillin/clavulanic acid (22.2% → 81.8%, p = 0.027)Rapid resistance escalation to a key broad-spectrum antibioticReview and restrict empirical veterinary use of amoxicillin/clavulanic acid; promote targeted therapy based on susceptibility testingMFL; VCZ; ZAMRA
Preserved susceptibility to carbapenems (imipenem, meropenem)Critical antimicrobials remain effectiveMaintain carbapenems as “last-resort” drugs; ban routine veterinary use to prevent resistance developmentMoH; MFL; ZAMRA
Fluctuating ciprofloxacin resistance (peaking > 50%)Risk to human medicine, as fluoroquinolones are important in both sectorsIntroduce stewardship protocols for fluoroquinolone use in livestock; require culture and sensitivity testing before administrationMoH; MFL; VCZ
Limited molecular epidemiology dataLack of genetic AMR surveillance limits understanding of resistance spreadInvest in laboratory capacity for molecular typing and AMR gene detection; integrate data with global platforms (FAO InFARM, WOAH ANIMUSE)MFL; ZNPHI; MoH; FAO; WOAH
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sinyawa, T.; Goma, F.; Chileshe, C.; Mudenda, N.B.; Mudenda, S.; Siame, A.; Simwinji, F.M.; Hadunka, M.A.; Chibwe, B.; Kaunda, K.; et al. Antimicrobial Resistance Profiles of Bacteria Isolated from the Animal Health Sector in Zambia (2020–2024): Opportunities to Strengthen Antimicrobial Resistance Surveillance and Stewardship Programs. Antibiotics 2025, 14, 1102. https://doi.org/10.3390/antibiotics14111102

AMA Style

Sinyawa T, Goma F, Chileshe C, Mudenda NB, Mudenda S, Siame A, Simwinji FM, Hadunka MA, Chibwe B, Kaunda K, et al. Antimicrobial Resistance Profiles of Bacteria Isolated from the Animal Health Sector in Zambia (2020–2024): Opportunities to Strengthen Antimicrobial Resistance Surveillance and Stewardship Programs. Antibiotics. 2025; 14(11):1102. https://doi.org/10.3390/antibiotics14111102

Chicago/Turabian Style

Sinyawa, Taona, Fusya Goma, Chikwanda Chileshe, Ntombi B. Mudenda, Steward Mudenda, Amon Siame, Fred Mulako Simwinji, Mwendalubi Albert Hadunka, Bertha Chibwe, Kaunda Kaunda, and et al. 2025. "Antimicrobial Resistance Profiles of Bacteria Isolated from the Animal Health Sector in Zambia (2020–2024): Opportunities to Strengthen Antimicrobial Resistance Surveillance and Stewardship Programs" Antibiotics 14, no. 11: 1102. https://doi.org/10.3390/antibiotics14111102

APA Style

Sinyawa, T., Goma, F., Chileshe, C., Mudenda, N. B., Mudenda, S., Siame, A., Simwinji, F. M., Hadunka, M. A., Chibwe, B., Kaunda, K., Mainda, G., Phiri, B. S. J., Kasanga, M., Mufwambi, W., Mukale, S., Bambala, A., Hangoma, J., Mabuku, N., Bowa, B., ... Chilengi, R. (2025). Antimicrobial Resistance Profiles of Bacteria Isolated from the Animal Health Sector in Zambia (2020–2024): Opportunities to Strengthen Antimicrobial Resistance Surveillance and Stewardship Programs. Antibiotics, 14(11), 1102. https://doi.org/10.3390/antibiotics14111102

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop